[摘要]目的 探讨头孢哌酮/舒巴坦联合盐酸莫西沙星治疗重症肺炎的临床效果。方法 选择2014年2月 ～2017年1月在我院诊断治疗的108例重症肺炎患者，依据治疗措施不同进行分组，对照组50例和头孢哌酮/舒巴坦联合盐酸莫西沙星组58例，观察两组重症肺炎患者治疗前后的炎症指标、白细胞计数水平情况和临床疗效情况。结果 两组患者治疗前的白细胞(WBC)、C反应蛋白(CRP)、降钙素原(PCT)情况比较，差异无统计学意义(P>0.05)，治疗后对照组和头孢哌酮/舒巴坦联合盐酸莫西沙星组的PCT、WBC、CRP均低于治疗前，差异有统计学意义(P<0.05)，头孢哌酮/舒巴坦联合盐酸莫西沙星组治疗后的PCT、WBC、CRP均低于对照组，差异有统计学意义(P<0.05)。头孢哌酮/舒巴坦联合盐酸莫西沙星组的临床总有效率高于对照组，差异有统计学意义(P<0.05)。结论 头孢哌酮/舒巴坦联合盐酸莫西沙星治疗重症肺炎患者的临床症状改善明显，效果良好，值得临床推广应用。

    [关键词]头孢哌酮/舒巴坦；盐酸莫西沙星；重症肺炎

    [中图分类号] R969.4 [文献标识码] A [文章编号] 1674-4721(2018)2(c)-0087-03

    [Abstract]Objective To investigate the clinical effect of Cefoperazone/Sulbactam combined with Moxifloxacin Hydrochloride in the treatment of severe pneumonia.Methods 108 patients with severe pneumonia diagnosed and treated in our hospital from February 2014 to January 2017 were divided into control group (50 cases) and Moxifloxacin Hydrochloride combined with Cefoperazone/Sulbactam group (58 cases) according to the different treatment measures.The inflammation index ......